ArticlePediatric cardiology2026
The Feasibility and Reproducibility of Measuring Myocardial Performance Index Using Two-Dimensional Phase Contrast Imaging in Patients with Congenital Heart Disease.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The myocardial performance index (MPI) integrates systolic and diastolic function to provide a geometry-independent measure of global ventricular performance. Despite its clinical utility, MPI remains underutilized in cardiovascular magnetic resonance (CMR), especially in patients with congenital heart disease (CHD). This study aimed to evaluate the feasibility and reproducibility of MPI measurement using mitral inflow phase-contrast CMR (PCCMR) in children and young adults with both normal cardiac anatomy and CHD, and to explore its relationship with ventricular function. A total of 124 participants, aged 4 to 27 years, who underwent clinically indicated CMR between August 2017 and December 2023, were retrospectively included. The cohort consisted of individuals with normal cardiac anatomy (n = 24), patients with repaired Tetralogy of Fallot (TOF) without significant residual lesions (n = 30), and patients with single-ventricle physiology following Fontan palliation (n = 70). MPI was calculated as (isovolumetric contraction time + isovolumetric relaxation time) divided by ejection time. Left ventricular ejection fraction (LVEF) was determined from standard cine CMR. Inter-reader agreement was excellent (r = 0.81-0.86, P < 0.001). MPI values were comparable between controls and TOF patients (0.32 ± 0.06 vs. 0.27 ± 0.08). In contrast, Fontan patients with systolic dysfunction had significantly higher MPI (0.65 ± 0.14) compared to those with preserved function (0.37 ± 0.05, P < 0.001), irrespective of systemic ventricle type. Additionally, MPI correlated with established prognostic markers for Fontan failure such as dilated volumes and AV valve regurgitation. These findings support PCCMR-derived MPI as a feasible, reproducible, and geometry-independent functional marker that complements other known biometrics such as ejection fraction, valve regurgitation and ventricular volumes, particularly in single ventricle patients.
Indexed as
Identifiers
40670760What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.